Why Clinical Trial Costs Are Skyrocketing Clinical trials sit at the heart of drug development, but their budgets are climbing faster than ever—with Phase III trials now frequently costing between $20 and $100 million. A big chunk of these costs stems from the sheer size and scope of patient recruitment and monitoring. When the wrong […]
“From buffer to Patients: Affinity assay predicting therapeutic behaviour in patients” Why Measuring Affinity in Native Plasma Matters for Therapeutic Development Affinity defines how strongly a therapeutic antibody binds to its target — and it is one of the most important parameters influencing efficacy, dosing, and clinical performance. Traditionally, affinity is measured in purified systems.
Leading to patient-dependent affinity Read More »
Expanding Capabilities in Antibody Detection: Launch of Our New Protein G Biosensor Probe We are excited to announce the release of our new Protein G biosensor probe, an important expansion of our biosensing portfolio. Complementing our existing Protein A probe, this new tool broadens antibody subclass and species detection with high sensitivity, reproducibility and specificity.
ProteinG sensor probe Read More »
Reliable EDC/NHS chemistry for confident, reproducible results When it comes to covalent amine immobilization via EDC/NHS chemistry, the quality of your reagents makes all the difference. Impure or underperforming coupling reagents can silently undermine your assay – reducing binding capacity, compromising functionality, and eroding reproducibility. Unfortunately, these issues often surface only at the end of
Introducing the Vixen Bio Amine Coupling Kit Read More »
Kinetic affinity comparison of candidates under actual clinical conditions for more predictive development Singledomain antibodies (sdAbs) have an improved capacity to penetrate tissues and reach obscured targets, making them powerful alternatives to conventional antibodies as therapeutic, whether it’s an inhibiting or neutralising function, or as the high precision binder in CAR-T therapy. Although these may
De-risk your sdAbs pipeline with superior selection in physiological conditions Read More »
